Ascendis Pharma A/S ADR (NASDAQ: ASND) kicked off on Monday, up 5.18% from the previous trading day, before settling in for the closing price of $129.87. Over the past 52 weeks, ASND has traded in a range of $111.09-$161.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 182.00%. While this was happening, its average annual earnings per share was recorded 15.52%. With a float of $59.25 million, this company’s outstanding shares have now reached $59.76 million.
In terms of profitability, gross margin is 84.82%, operating margin of -96.44%, and the pretax margin is -127.34%.
Ascendis Pharma A/S ADR (ASND) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Ascendis Pharma A/S ADR is 0.86%, while institutional ownership is 105.10%. The most recent insider transaction that took place on Dec 10 ’24, was worth 273,621. Before that another transaction happened on Dec 10 ’24, when Company’s Officer proposed sale 2,119 for $129.13, making the entire transaction worth $273,621.
Ascendis Pharma A/S ADR (ASND) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 15.52% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 38.10% during the next five years compared to -19.87% drop over the previous five years of trading.
Ascendis Pharma A/S ADR (NASDAQ: ASND) Trading Performance Indicators
Take a look at Ascendis Pharma A/S ADR’s (ASND) current performance indicators. Last quarter, stock had a quick ratio of 0.84. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 23.03.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -8.10, a number that is poised to hit -1.35 in the next quarter and is forecasted to reach -3.83 in one year’s time.
Technical Analysis of Ascendis Pharma A/S ADR (ASND)
Looking closely at Ascendis Pharma A/S ADR (NASDAQ: ASND), its last 5-days average volume was 0.38 million, which is a drop from its year-to-date volume of 0.45 million. As of the previous 9 days, the stock’s Stochastic %D was 53.79%. Additionally, its Average True Range was 5.09.
During the past 100 days, Ascendis Pharma A/S ADR’s (ASND) raw stochastic average was set at 57.40%, which indicates a significant decrease from 89.96% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 34.42% in the past 14 days, which was lower than the 47.07% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $129.15, while its 200-day Moving Average is $135.31. However, in the short run, Ascendis Pharma A/S ADR’s stock first resistance to watch stands at $139.50. Second resistance stands at $142.40. The third major resistance level sits at $147.15. If the price goes on to break the first support level at $131.85, it is likely to go to the next support level at $127.10. Should the price break the second support level, the third support level stands at $124.20.
Ascendis Pharma A/S ADR (NASDAQ: ASND) Key Stats
The company with the Market Capitalisation of 8.16 billion has total of 60,642K Shares Outstanding. Its annual sales at the moment are 288,670 K in contrast with the sum of -521,070 K annual income. Company’s last quarter sales were recorded 63,590 K and last quarter income was -109,080 K.
